HOME >> BIOLOGY >> NEWS
Studies show success of Mectizan partnerships

The development of the drug Mectizan (ivermectin) and its distribution worldwide have radically altered the consequences of onchocerciasis, or river blindness, which once blinded millions in Africa, and Latin America. Researchers at the Johns Hopkins Bloomberg School of Public Health conducted four new studies evaluating the Mectizan Donation Program, which was established by Merck and Co. Inc., the makers of Mectizan. They concluded that the now 17-year old Mectizan Donation Program is a successful and cost effective program for preventing the debilitating effects of river blindness. The researchers also believe that the public-private partnership forged by Merck through the Mectizan Donation Program should serve as a model for other companies and aid organizations seeking to prevent and treat other illnesses worldwide, such as AIDS and malaria. The studies are published in the current issue the journal Tropical Medicine and International Health.

On May 14, 2004, the School of Public Health and Merck and Co. Inc., will mark the successful work of the Mectizan Distribution Program with a symposium, "Controlling River Blindness: Achievements of a Public-Private Partnership." The event will be held from 12:15-1:30 p.m. at the School of Public Health in Baltimore, Md. and will feature discussions of the latest study findings from researchers from the School of Public Health and representatives from Merck and the Mectizan Donation Program.

"The Mectizan Donation Program is really one of the great public health success stories. It is the benchmark for all other disease prevention efforts in the developing world," said Gilbert Burnham, MD, one of the study authors and an associate professor in the School's Department of International Health.

Ivermectin, the compound from which Mectizan is derived, was originally found to be effective against parasites in farm animals. Realizing its potential as a human medicine, Merck and WHO conducted seven years of
'"/>

Contact: Tim Parsons
paffairs@jhsph.edu
410-955-6878
Johns Hopkins University Bloomberg School of Public Health
10-May-2004


Page: 1 2

Related biology news :

1. Monkey business: Studies show tiny callimicos have unusual characteristics
2. Studies offer new insight into HIV vaccine development
3. Studies suggest brain injury results from developmental exposure to alcohol, anesthesia, and lead
4. Studies show preventive value of food supplements
5. Studies probe rapid evolution of Chinese tallow trees
6. Studies of rare blood syndrome yield novel route to cancer
7. Studies dispute ultraviolet effect on amphibian population declines
8. Studies of spiders silk reveal unusual strength
9. Studies of genes in mice and common worm may accelerate research on blood diseases, cancers
10. Studies offer data on potential impact of Reminyl on caregiver burden in Alzheimers disease
11. Studies: Floyd, other major hurricanes of 99 caused significant changes in nations largest lagoonal estuary

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments is ... Nanoscience Analytical offers a broad range of contract analysis services for advanced ...
Breaking Biology Technology:
Cached News: